Nina Schatz‐Siemers

Nina Schatz‐Siemers

Auto-generated profile, based on publicly available information

Nina Schatz‐Siemers

Department of Pathology and Laboratory Medicine Weill Cornell Medicine New York New York USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2019 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
NSNina Schatz‐Siemers
Nina Schatz‐Siemers
TBTamar C Brandler
Tamar C Brandler
TOThaira Oweity
Thaira Oweity
WSWei Sun
Wei Sun
AHAndrea Hernandez
Andrea Hernandez
PLPascale Levine
Pascale Levine

11 January 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
MMMargaret McKelvy
Margaret McKelvy
STSrishti Tyagi
Srishti Tyagi
EHEmilie Vander Haar
Emilie Vander Haar
MLMadhavi Lakkaraja
Madhavi Lakkaraja
TTTim Tomy
Tim Tomy
JBJames Bussel
James Bussel
Background: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) ensues from parental incompatibility for platelet alloantigens with maternal sensitization. HPA‐1a/1b incompatibility is the most common cause of FNAIT in Caucasians. Placental villitis and lower birthweight in FNAIT suggest anti‐HPA‐1a may have effects beyond inducing thrombocytopenia. Objectives: Does FNAIT secondary to anti‐HPA‐1a result in smaller newborns and, the corollary, does antenatal management of FNAIT increase birthweight? Study design: Birthweights of 270 FNAIT‐affected newborns from a randomized clinical trial and a NAITbabies.org survey (135 paired siblings) were compared with those of published controls and treated to untreated FNAIT‐affected siblings. Birthweights were converted to percentiles to account for gestational age, sex, and role of birth order in birth weight. Body weights of FNAIT‐affected and ‐unaffected pups in a mouse FNAIT model were analyzed. Results: Untreated siblings in both the clinical trial and NAITbabies.org cohorts were not small, compared with normal controls. However, treated siblings in both cohorts had significantly higher birthweight percentiles compared with their previous untreated affected sibling. After accounting for gestational age, sex, and birth order, increased birthweight percentile in treated compared with the untreated siblings remained significant in both cohorts. FNAIT‐affected neonatal mice had lower bodyweights than FNAIT‐unaffected pups. Conclusions: Untreated FNAIT‐affected newborns were not small; however, treatment of FNAIT‐affected pregnancies increased newborn birthweights despite corrections to account for other factors that might have influenced the results. High dose IVIG is believed to “block” FcRn and lower maternal anti‐HPA‐1a levels, and thus increase birthweights by reducing levels of maternal anti‐HPA‐1a and reducing placental villitis.